Due to a run on AstroGlide at all local pharmacies on the east end, there is a veritable crisis in PT. FLML management is on the case, however, to provide an over the counter micro pump version. Can they get it passed by the FDA by this weekend? Barney Frank is making calls to Washington as we speak...Anderson and Boris are beside themselves...
I would refer you to "Elements of Style" by Strunk and White
English is obviously not your native language so where are you from?
Make sense since some posters here think the these two plan on sharing some quality pillow talk at the Bridle suite at the Eastmoor's Memorial Day festivities this weekend. They will be required, however, to pay a huge cover charge at the door, guarded by Mary Jo White.
Like Bob Dylan said, "Ah but he's been to the finest schools.."
Strong revenue growth in 1Q15 exceeds our and Street expectations, with
continued pipeline progress; reiterate Market Outperform rating and $25 price
target on Flamel Technologies. Flamel reported 1Q15 earnings that, at first look,
appeared to miss our and consensus estimates. However, the company deferred ~
$32MM of revenue in 1Q15, based on its sell through accounting methodology, and we
estimate sales to the wholesalers during the quarter of ~$57-58MM, exceeding both our
and consensus estimates. We view the financial performance in 1Q15 as strong and
our confidence in guidance (total sales $170-185MM) is reaffirmed by management’s
comments that the current sales run rate is ~$20MM per month. Additionally, we
continue to anticipate value-driving pipeline catalysts in 2015, most importantly in our
view the FDA meeting for the sodium oxybate program in ~mid-2015. Our $25 price
target is based on our projections for product revenues/royalties and the value of the
company's core drug delivery technologies.
He is expected this weekend at the Pub's backdoor decked out in leather mask and whip with Boris in tow wearing leash and nipple ring.
Us folk on the buy side do not like to get blindsided. Anderson should have flagged this accounting treatment during last q call. Instead, he panicked and took the weasel way out. Kaplan and his clients must be very upset with how this was handled. This development will have future unintended consequences by increasing the discount rate on FLML because the buy side will always wonder if they are getting full disclosure in a timely manner, causing more big, unexplained swings in the stock price.
Boris did not get the bright idea to ask such a question two days before earnings and even if he did, management could not selectively disclose specific, material information to a single analyst, leaving the rest of the street in the dark and screwing the buy side. Wake up
Houston - we have a problem. There is an uncanny resemblance between this morning's press release concerning deferred revenue and the Suntrust report issued two days prior. As I posted that day, an analyst cannot make this stuff up and had to have had a reasonable basis for substantially revising down his Street-high estimates. There is a regulation called FD.
JMP SECURITIES BUTLER J 53.2 20-Mar-15
LADENBURG THALMANN & CO. KAPLAN M 67.07 20-Mar-15
LEERINK PARTNERS LLC GERBERRY J 42 20-Mar-15
ROTH CAPITAL PARTNERS LLC HENRY S 37.7 19-Mar-15
SUNTRUST ROBINSON HUMPHREY BORIS J 32 12-May-15